Our study demonstrates the potential of a CBP inhibitor therapy enhances of the binding of β-catenin to p300 which mediated cell differentiation and senescence in BCR-ABL-wild-type and -T315I mutant CML. The gene discussed is EP300; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.